RayzeBio (BMS)
RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.
RYZ101 (225Ac-DOTATATE), 225Ac-PSMA (RYZ801), in-house 225Ac manufacturing.
Pages like this
not linked directly; found by shared links- TrialACTION-1
Shares Actinium-225 DOTATATE, Targeted alpha therapy, Neuroendocrine tumours.
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 DOTATATE, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- TrialALPHAMEDIX-02
Shares Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
- CompanyITM Isotope Technologies Munich
Shares Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
- CompanyRadioMedix
Shares Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
- CompanyOrano Med
Shares Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyFusion Pharmaceuticals (AstraZeneca)
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.